Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
CADILA HEALTHCARE | AUROBINDO PHARMA | CADILA HEALTHCARE/ AUROBINDO PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 28.8 | 17.6 | 163.6% | View Chart |
P/BV | x | 4.6 | 3.8 | 121.8% | View Chart |
Dividend Yield | % | 0.7 | 0.3 | 269.2% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CADILA HEALTHCARE Mar-20 |
AUROBINDO PHARMA Mar-19 |
CADILA HEALTHCARE/ AUROBINDO PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 352 | 830 | 42.4% | |
Low | Rs | 207 | 527 | 39.2% | |
Sales per share (Unadj.) | Rs | 139.2 | 333.9 | 41.7% | |
Earnings per share (Unadj.) | Rs | 11.8 | 40.4 | 29.2% | |
Cash flow per share (Unadj.) | Rs | 18.6 | 51.8 | 35.9% | |
Dividends per share (Unadj.) | Rs | 3.50 | 2.50 | 140.0% | |
Dividend yield (eoy) | % | 1.3 | 0.4 | 340.0% | |
Book value per share (Unadj.) | Rs | 101.4 | 237.1 | 42.7% | |
Shares outstanding (eoy) | m | 1,023.74 | 585.91 | 174.7% | |
Bonus/Rights/Conversions | - | ESOP | - | ||
Price / Sales ratio | x | 2.0 | 2.0 | 98.8% | |
Avg P/E ratio | x | 23.7 | 16.8 | 141.2% | |
P/CF ratio (eoy) | x | 15.0 | 13.1 | 114.8% | |
Price / Book Value ratio | x | 2.8 | 2.9 | 96.3% | |
Dividend payout | % | 29.8 | 6.2 | 480.2% | |
Avg Mkt Cap | Rs m | 286,033 | 397,569 | 71.9% | |
No. of employees | `000 | 13.4 | 17.9 | 75.1% | |
Total wages/salary | Rs m | 24,145 | 25,849 | 93.4% | |
Avg. sales/employee | Rs Th | 10,632.7 | 10,956.9 | 97.0% | |
Avg. wages/employee | Rs Th | 1,801.2 | 1,447.7 | 124.4% | |
Avg. net profit/employee | Rs Th | 898.5 | 1,324.3 | 67.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 142,531 | 195,636 | 72.9% | |
Other income | Rs m | 1,139 | 1,553 | 73.3% | |
Total revenues | Rs m | 143,670 | 197,189 | 72.9% | |
Gross profit | Rs m | 24,198 | 39,519 | 61.2% | |
Depreciation | Rs m | 6,965 | 6,680 | 104.3% | |
Interest | Rs m | 3,418 | 2,626 | 130.2% | |
Profit before tax | Rs m | 14,954 | 31,767 | 47.1% | |
Minority Interest | Rs m | 288 | 27 | 1,066.7% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -881 | 0.0% | |
Tax | Rs m | 3,198 | 7,269 | 44.0% | |
Profit after tax | Rs m | 12,044 | 23,645 | 50.9% | |
Gross profit margin | % | 17.0 | 20.2 | 84.0% | |
Effective tax rate | % | 21.4 | 22.9 | 93.5% | |
Net profit margin | % | 8.5 | 12.1 | 69.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,154 | 153,645 | 56.7% | |
Current liabilities | Rs m | 82,694 | 120,429 | 68.7% | |
Net working cap to sales | % | 3.1 | 17.0 | 18.4% | |
Current ratio | x | 1.1 | 1.3 | 82.6% | |
Inventory Days | Days | 71 | 135 | 52.8% | |
Debtors Days | Days | 94 | 64 | 147.3% | |
Net fixed assets | Rs m | 133,236 | 103,909 | 128.2% | |
Share capital | Rs m | 1,024 | 586 | 174.8% | |
"Free" reserves | Rs m | 102,733 | 138,322 | 74.3% | |
Net worth | Rs m | 103,757 | 138,908 | 74.7% | |
Long term debt | Rs m | 32,146 | 1,800 | 1,786.4% | |
Total assets | Rs m | 236,866 | 264,544 | 89.5% | |
Interest coverage | x | 5.4 | 13.1 | 41.0% | |
Debt to equity ratio | x | 0.3 | 0 | 2,391.6% | |
Sales to assets ratio | x | 0.6 | 0.7 | 81.4% | |
Return on assets | % | 6.5 | 9.9 | 65.7% | |
Return on equity | % | 11.6 | 17.0 | 68.2% | |
Return on capital | % | 13.7 | 23.8 | 57.6% | |
Exports to sales | % | 0 | 49.6 | 0.0% | |
Imports to sales | % | 0 | 18.8 | 0.0% | |
Exports (fob) | Rs m | NA | 97,091 | 0.0% | |
Imports (cif) | Rs m | NA | 36,741 | 0.0% | |
Fx inflow | Rs m | 52,752 | 97,316 | 54.2% | |
Fx outflow | Rs m | 14,504 | 40,589 | 35.7% | |
Net fx | Rs m | 38,248 | 56,727 | 67.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 25,054 | 16,220 | 154.5% | |
From Investments | Rs m | -10,123 | -28,768 | 35.2% | |
From Financial Activity | Rs m | -10,942 | 19,191 | -57.0% | |
Net Cashflow | Rs m | 3,989 | 6,656 | 59.9% |
Indian Promoters | % | 74.8 | 54.1 | 138.3% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.3 | 8.0 | 104.4% | |
FIIs | % | 5.9 | 27.7 | 21.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 11.0 | 10.2 | 107.8% | |
Shareholders | 44,069 | 69,601 | 63.3% | ||
Pledged promoter(s) holding | % | 0.0 | 8.6 | - |
Compare CADILA HEALTHCARE With: PFIZER ABBOTT INDIA PANACEA BIOTECH WYETH GSK PHARMA
Compare CADILA HEALTHCARE With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed a sharp sell-off during closing hours yesterday and ended lower.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More